<DOC>
	<DOCNO>NCT02817958</DOCNO>
	<brief_summary>Squamous cell carcinoma penis rare tumor Europe , whose prognosis survival influence metastatic lymph node involvement . Its frequency France estimate less 1 % human cancer . This spread follow sequential process via superficial deep inguinal lymph node pelvic lymph node metastatic dissemination . The management inguinal area cornerstone penile cancer . It curative 80 % patient 1 2 inguinal metastasis . 5-years overall survival average 85 % pN0 patient 40 % pN + patient . For pN + patient , 5-years overall survival 70 80 % pN1 ( 1 lymph node invasion ) , 30 40 % pN2 0 10 % pN3 . The risk local recurrence 5-10 % pN0 20-30 % pN + local treatment lymphadenectomy alone without chemotherapy . The average time recurrence 10 month . Disease-free survival 5 year 75-85 % pN0 30-45 % pN + . Its indication depend clinical examination ( presence absence lymph node palpate ) risk nodal disease ( ≥ pT1bG2 ) . Currently , fine needle biopsy best clinical diagnosis method simple , low risk possible consultation . When result positive , allow early dissection . Single double fine needle biopsy use cN + patient . For patient risk lymp node involvement ( cN0 ≥ pT1B G2 ) , sentinel node diagnosis may follow modified bilateral lymphadenectomy . Although lymphadenectomy alone curator action , sometimes remain insufficient patient metastatic lymph node involvement . Therefore seem important develop multimodal approach management patient order increase response rate treatment survival . From Phase II trial conduct 30 patient , combination TIP ( paclitaxel , ifosfamide cisplatin ) appear efficacy / toxicity acceptable . The TIP protocol therefore chosen trial adjuvant neo-adjuvant treatment patient high risk lymph node involvement ( cN0 ≥ pT1B G2 ) , inguinal mobile palpate lymph node ( cN + ) respectively , lymph node involvement proven ( pN + ) .</brief_summary>
	<brief_title>Evaluation Lymphadenectomy Chemotherapy TIP Inguinal Lymph Nodes Squamous Cell Carcinoma Penis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Penile Neoplasms</mesh_term>
	<criteria>1. penile tumor histologically proven whatever initial treatment penile tumor : amputation conservative surgery brachytherapy , 2 . Mobile palpate lymph node ( stage cN1 cN2 ) whatever T stage , Or If palpate lymph node ( cN0 ) , patient nod involvement risk ≥pT1b / Grade 2 3 . Metastatic lymph node involvement 4 . Patients M0 Mx , 5 . Age≥18 ans , 6 . ECOG 01 , 7 . Leucocytes ≥ 1.5 G/L , 8 . Hemoglobin ≥ 9 g/dL , 9 . Platelets ≥100 000/mm3 , 10 . Normal calcemia kaliemia , 11 . AST ALT ≤ 1.5 LNS ; total bilirubin ≤ 1.5 LNS ( 3 LNS case Gilbert disease ) ; PAL &lt; 2 LNS , 12 . Creatinine clearance ≥ 60 mL/mn ( MDRD method ) , 13 . FEVG &gt; 50 % , 14 . Patients receive , read information note sign consent , 15 . Reproductive age patient agree use two method birth control ( one patient one partner ) duration study 6 month last dose treatment , 16 . Patients able comply protocol requirement ( schedule visit , treatment plan , clinical , paraclinical , biological procedure Protocol ) 17 . Patients undergo social security scheme . 1 . Fixed inguinal lymph node ( cN3 ) 2 . Iliac lymph node ( cN3 ) 3 . Patients pN3 4. prior chemotherapy squamous cell carcinoma penis , 5 . Againstindication chemotherapy know hypersensitivity cisplatin , ifosfamide paclitaxel , 6 . Patients treat phenytoin , 7 . Patients hear loss &gt; Grade 1 ( CTCAE V4.03 ) 8 . Patients cardiopulmonary diseaseindicating overhydration , 9 . History cancer within 5 year prior inclusion trial cutaneous basal cell , 10 . Patient receive live attenuated vaccine within 30 day prior inclusion , 11 . Patients already include another clinical trial receive experimental treatment within 30 day prior inclusion trial , 12 . Patients deprive lyberty court protection include guardianship , 13 . Severe systemic disease uncontrolled chronic acute illness incompatible patient 's participation trial accord investigator , 14. immunocompromised patient include know seropositivity ( HIV ) , 15 . Patients mental impairment prevents understand protocol psychological state , family , sociological geographical condition would allow compliance protocol plan followup condition , accord investigator , would prevent participation patient test . These condition assess inclusion patient .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>inguinal lymph node</keyword>
	<keyword>penile cancer</keyword>
	<keyword>squamous</keyword>
	<keyword>TIP chemotherapy</keyword>
</DOC>